Loading
Dual Anti-platelet Therapy / Platelet Aggregation Inhibitors / Antiplatelet Therapy · Journal article
Renal Failure · July 13, 2026
Encouraging direction, but not yet definitive.
This national cohort study of 4,800 ACS patients treated with PCI found no association between DAPT duration (1–3, 4–6, or ≥7 months) and cardiovascular outcomes overall or stratified by CKD status. However, DAPT duration ≥7 months was associated with significantly higher odds of major bleeding in patients with claims-defined CKD (aOR 29.7), although the authors characterize this as exploratory given low event rates and observational design.
Population-based, retrospective cohort study. Patients ≥20 years admitted for acute coronary syndrome (unstable angina, NSTEMI, or STEMI) treated with PCI in Taiwan, 2001–2018, with complete baseline demographic and comorbidity data; excluded prior CABG, in-hospital death, and those not receiving DAPT for ≥1 month.. Intervention: Dual antiplatelet therapy (aspirin + clopidogrel) for ≥7 months after PCI. Compared with: Dual antiplatelet therapy for 1–3 months and 4–6 months after PCI. n = 4,800. Taiwan National Health Insurance Research Database (nationwide coverage >99% of population; ~23 million people).
Among 4,800 ACS patients (median age 62 years, 77% male), no significant differences in cardiovascular events across DAPT duration groups DAPT duration ≥7 months associated with higher incidence of major bleeding in CKD patients (aOR = 29.7, 95% CI: 1.80–491.05, p = 0.018) No associations between DAPT duration and cardiovascular outcomes identified in patients with or without CKD
Bleeding events in CKD subgroup reported as low-frequency; wide confidence interval (1.80–491.05) indicates imprecision Observational design cannot establish causation; potential for unmeasured confounding (e.g., bleeding risk scores, medication adherence, indication for DAPT duration)
This observational evidence does not support prolonging DAPT beyond 6 months for cardiovascular benefit in ACS patients after PCI. The increased bleeding risk in patients with CKD receiving prolonged DAPT (≥7 months) suggests that individualized, risk-stratified decisions on DAPT duration are warranted, particularly in patients with renal impairment; however, findings are exploratory and should not yet drive practice change.
Observational cohort study with a large sample (4,800 patients) from a national database showing no benefit of prolonged DAPT on cardiovascular outcomes in ACS patients, but identifying a signal of increased bleeding in CKD subgroup; findings are exploratory and require confirmation.
As stated by the source record.
Quoted from the source exactly as published.
This observational evidence does not support prolonging DAPT beyond 6 months for cardiovascular benefit in ACS patients after PCI. The increased bleeding risk in patients with CKD receiving prolonged DAPT (≥7 months) suggests that individualized, risk-stratified decisions on DAPT duration are warranted, particularly in patients with renal impairment; however, findings are exploratory and should not yet drive practice change.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) reduces thrombotic risk in acute coronary syndrome (ACS) but may increase bleeding, especially in chronic kidney disease (CKD). This study evaluated the impact of different DAPT durations on cardiovascular and bleeding outcomes in ACS patients with and without CKD. Using the Taiwan National Health Insurance Research Database (2001-2018), patients ≥20 years with ACS who underwent PCI and received clopidogrel plus aspirin for ≥1 month were analyzed. Primary outcomes were cardiovascular events and bleeding events. Subgroup analysis was conducted by CKD status, which was defined using claims-based International Classification of Diseases, Ninth and Tenth Revision (ICD-9/ICD-10) diagnostic codes. Among 4,800 patients with ACS identified (median age: 62 years; 77% male), there were no significant differences in cardiovascular events across DAPT duration groups. No associations between DAPT duration and cardiovascular outcomes were identified in patients with or without CKD. However, DAPT duration ≥7 months was associated with a higher incidence of other major bleeding in patients with CKD (adjusted odds ratio [aOR] = 29.7, 95% confidence interval [CI]: 1.80-491.05, p = 0.018). In patients undergoing PCI for ACS, no clear association was observed between longer DAPT duration and reduced cardiovascular events. In prespecified subgroup analyses, prolonged DAPT was associated with a higher incidence of bleeding events among patients with claims-defined CKD; however, this finding should be interpreted as exploratory given the observational design and low event rates. These results highlight the importance of individualized decision-making regarding DAPT duration, particularly in patients with increased bleeding susceptibility.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.